ProPhase Labs, Inc. Lease, Cost
ProPhase Labs, Inc. (PRPH) reported Lease, Cost of $204.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2023-05-12
- ProPhase Labs, Inc. lease, cost for the quarter ending 2023-03-31 was $204.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. lease, cost for the quarter ending 2022-12-31 was $204.00K, a 0.49% decline year-over-year.
- ProPhase Labs, Inc. lease, cost for the quarter ending 2022-09-30 was $204.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. lease, cost for the quarter ending 2022-06-30 was $204.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. lease, cost for fiscal 2022 was $816.00K, a 0.00% change from fiscal 2021.
- ProPhase Labs, Inc. lease, cost for fiscal 2021 was $816.00K, a 6700.00% increase from fiscal 2020.
- ProPhase Labs, Inc. lease, cost for fiscal 2020 was $12.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $204.00K 10-Q · filed 2023-05-12 | $408.00K derived: sum of 2 quarters · filed 2023-05-12 | $612.00K derived: sum of 3 quarters · filed 2023-05-12 | $816.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $408.00K derived: sum of 2 quarters · filed 2023-03-29 | $612.00K derived: sum of 3 quarters · filed 2023-03-29 | $816.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $204.00K 10-Q · filed 2022-11-10 | $408.00K derived: sum of 2 quarters · filed 2022-11-10 | $612.00K 10-Q · filed 2022-11-10 | $817.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | $204.00K 10-Q · filed 2022-08-12 | $408.00K 10-Q · filed 2022-08-12 | $613.00K derived: sum of 3 quarters · filed 2023-05-12 | $817.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | $204.00K 10-Q · filed 2023-05-12 | $409.00K derived: sum of 2 quarters · filed 2023-05-12 | $613.00K derived: sum of 3 quarters · filed 2023-05-12 | $817.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $409.00K derived: sum of 2 quarters · filed 2023-03-29 | $613.00K derived: sum of 3 quarters · filed 2023-03-29 | $816.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $204.00K 10-Q · filed 2022-11-10 | $408.00K derived: sum of 2 quarters · filed 2022-11-10 | $611.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $204.00K 10-Q · filed 2022-08-12 | $408.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $204.00K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $12.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |